serena williams using glp 1 SerenaWilliams is opening up about her experience with the GLP-1 drug Zepbound. The recent public discourse around Williams's body—online commenters have noticed a change in her physique and demanded to know how Serena Williams and the coming

The SELECT trial builds on these results, showing that once-weekly semaglutide resulted in a 20% reduction in the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with pre-existing cardiovascular disease and BMI 27kg/m 2

Consumers evaluating telehealth-based compounded prescriptions in 2026 are increasingly advised to review both regulatory context and product-specific information before making decisions - and that's especially true when a company is generating this much attention from this many directions at once

A former Chief Scientist (Informatics) and CIO at the US FDA , he has held senior leadership roles across academia, government, and the pharmaceutical industry

doi:10.1111/j.1365-2982.2008.01246.x Amato A, Cinci L, Rotondo A, et al

Ro chose to make the tool free for anyone to use because a "basic inventory management system" for GLP-1s does not exist, making it a major contribution to the broader community that relies on those medications, according to Reitano

Rondas, D., DHertog, W., Overbergh, L